08:00 AM EDT, 09/09/2026 (MT Newswires) -- Finnish biotechnology company Nightingale Health (HEALTH.HE) and its Croatian peer Genom are partnering to deliver a blood-based risk detection test to Croatian clinics and laboratories. The Nightingale Health Check estimates a person's 10-year risk of five chronic diseases using one blood sample, according to a Wednesday release. Three pilot programs have been completed, with the companies planning to launch the test nationwide across Genom's network of clinics and labs later in 2026.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.